Guojin Securities released a research report on April 23 stating that it gave Tebao Biotech (688278.SH) a purchase rating. The main reasons for the rating include: 1) clinical evidence of hepatitis B cure continues to accumulate, and Pegobin continues to
Haitong International released a research report on April 15 stating that it gave Tebao Biotech (688278.SH) an superior rating to the market, and the target price was 89.20 yuan. The main reasons for the rating include: 1) continued revenue growth driven
Jefferies Adjusts Takara Bio's Price Target to 1,900 Yen From 2,000 Yen, Keeps at Hold
No Data